The diverse radiation types in medical treatments and the natural environment elicit complex biological effects on both cancerous and non-cancerous tissues.Radiation therapy(RT)induces oncological responses,from molec...The diverse radiation types in medical treatments and the natural environment elicit complex biological effects on both cancerous and non-cancerous tissues.Radiation therapy(RT)induces oncological responses,from molecular to phenotypic alterations,while simultaneously exerting toxic effects on healthy tissue.N^(6)-methyladenosine(m^(6)A),a prevalent modification on coding and non-coding RNAs,is a key epigenetic mark established by a set of evolutionarily conserved enzymes.The interplay between m^(6)A modification and radiobiology of cancerous and non-cancerous tissues merits in-depth investigation.This review summarizes the roles of m^(6)A in the biological effects induced by ionizing radiation and ultraviolet(UV)radiation.It begins with an overview of m^(6)A modification and its detection methods,followed by a detailed examination of how m^(6)A dynamically regulates the sensitivity of cancerous tissues to RT,the injury response in non-cancerous tissues,and the toxicological effects of UV exposure.Notably,this review underscores the importance of novel regulatory mechanisms of m^(6)A and their potential clinical applications in identifying epigenetically modulated radiation-associated biomarkers for cancer therapy and estimation of radiation dosages.In conclusion,enzyme-mediated m^(6)A-modification triggers alterations in target gene expression by affecting the metabolism of the modified RNAs,thus modulating progression and radiosensitivity in cancerous tissues,as well as radiation effects on normal tissues.Several promising avenues for future research are further discussed.This review highlights the importance of m^(6)A modification in the context of radiation biology.Targeting epi-transcriptomic molecules might potentially provide a novel strategy for enhancing the radiosensitivity of cancerous tissues and mitigating radiation-induced injury to normal tissues.展开更多
Objective:To evaluate the pain degree of the patients with chronic non-cancer pain by using the evaluation model constituted by heart rate variability,anxiety and depression scale and quality of life rating scale.This...Objective:To evaluate the pain degree of the patients with chronic non-cancer pain by using the evaluation model constituted by heart rate variability,anxiety and depression scale and quality of life rating scale.This study also aims toevaluate the efficacy after treatment and nursing intervention.Methods:100 patients with chronic non-cancer pain treated in the hospital from February 2016 to April 2017 were selected to compare their heart rate variability,score of anxiety and depression,score of quality of life and NRS score before and after treatment and nursing intervention.Results:After treatment and nursing intervention,the heart rate variability time domain SDNN significantly increased(P<0.05).The score of anxiety and depression was lower than that before intervention(P<0.05)while the scores of various dimensions of quality of life were higher than those before intervention(P<0.05).The results also showed that NRS score was lower than that before intervention(P<0.05).Conclusion:These findings suggest that the measurement combination of heart rate variability,anxiety and depression scale and quality of life rating scale can be used as an evaluation model to evaluate the pain degree of the patients with chronic non-cancer pain the efficacy after treatment and nursing intervention,which is worthy of clinic application.展开更多
CD47 is an immune checkpoint widely regarded as a‘don't eat me’signal.CD47-based anti-cancer therapy has received considerable attention,with a significant number of clinical trials conducted.While anti-cancer t...CD47 is an immune checkpoint widely regarded as a‘don't eat me’signal.CD47-based anti-cancer therapy has received considerable attention,with a significant number of clinical trials conducted.While anti-cancer therapies based on CD47 remain a focal point of interest among researchers,it is noteworthy that an increasing number of studies have found that CD47-based therapy ameliorated the pathological status of non-cancer diseases.This review aims to provide an overview of the recent progress in comprehending the role of CD47-based therapy in non-cancer diseases,including diseases of the circulatory system,nervous system,digestive system,and so on.Furthermore,we sought to delineate the promising mechanisms of CD47-based therapy in treating non-cancer diseases.Our findings suggest that CD47-based agents may exert their effect by regulating phagocytosis,regulating T cells,dendritic cells,and neutrophils,and regulating the secretion of cytokines and chemokines.Additionally,we put forward the orientation of further research to bring to light the potential of CD47 and its binding partners as a target in non-cancer diseases.展开更多
Enhancer of Zeste homolog 2(EzH2),a histone methyltransferase within polycomb repressive complex 2(PRC2),plays a crucial role in epigenetic regulation by silencing gene expression through trimethylation of histone 3 a...Enhancer of Zeste homolog 2(EzH2),a histone methyltransferase within polycomb repressive complex 2(PRC2),plays a crucial role in epigenetic regulation by silencing gene expression through trimethylation of histone 3 at lysine 27(H3K27me3).Beyond its well-documented oncogenic functions,emerging research has revealed EZH2's involvement in various non-cancerous pathologies.For instance,EZH2 is critical in regulating immune responses,particularly in modulating T cell differentiation and cytokine production,which affects inflammation and immune homeostasis.EzH2 also controls fibroblast activation and extracellular matrix(ECM)remodeling,influencing critical processes such as cell differentiation,tissue repair and energy homeostasis.Additionally,EzH2's epigenetic regulation of neuroinflammatory processes is linked to neuronal health and survival.Recent advancements in EZH2 inhibitor therapies demonstrate promising potential for treating a range of non-cancerous conditions,with preclinical trials suggesting efficacy in mitigating disease progression.This review highlights the expanding functional scope of EZH2,emphasizing its epigenetic mechanisms and the therapeutic opportunities for targeting EZH2 in non-cancerous diseases.展开更多
Flexible polymeric patches find widespread applications in biomedicine because of their biological and tunable features including excellent patient compliance,superior biocompatibility and biodegradation,as well as hi...Flexible polymeric patches find widespread applications in biomedicine because of their biological and tunable features including excellent patient compliance,superior biocompatibility and biodegradation,as well as high loading capability and permeability of drug.Such polymeric patches are classified into microneedles(MNs),hydrogel,microcapsule,microsphere and fiber depending on the formed morphology.The combination of nanomaterials with polymeric patches allows for improved advantages of increased curative efficacy and lowered systemic toxicity,promoting on-demand and regulated drug administration,thus providing the great potential to their clinic translation.In this review,the category of flexible polymeric patches that are utilized to integrate with nanomaterials is briefly presented and their advantages in bioapplications are further discussed.The applications of nanomaterials embedded polymeric patches in non-cancerous diseases were also systematically reviewed,including diabetes therapy,wound healing,dermatological disease therapy,bone regeneration,cardiac repair,hair repair,obesity therapy and some immune disease therapy.Alternatively,the limitations,latest challenges and future perspectives of such biomedical therapeutic devices are addressed.展开更多
Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, w...Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, which are current worldwide standards for patient selection, several biological tumor factors have been identified to affect cancer-specific outcome. In particular, grading and vascular tumor invasions were shown to correlate with aggressive biological tumor behavior and poor survival following LT. Identifying tumors with favorable biology is one important approach for expanding the pool of eligible liver recipients beyond the Milan burden limits. Improving the immunological state and condition for appropriate defense against circulating cancer cell attack may be another important prognostic aspect. Therefore, there is increasing interest in non-cancer factors related to the peritransplant period that may influence the oncological outcome by providing negative immunomodulatory actions. Considering and modulation of these non-HCC factors of prognosis might contribute in safely expanding the HCC LT selection criteria.展开更多
基金supported by grants from the National Natural Science Foundation of China(Grant No.82173467 and 82273577)CAMS Innovation Fund for Medical Sciences(Grant Nos.CIFMS,2022-I2M-2-003 and 2021-I2M-1-042).
文摘The diverse radiation types in medical treatments and the natural environment elicit complex biological effects on both cancerous and non-cancerous tissues.Radiation therapy(RT)induces oncological responses,from molecular to phenotypic alterations,while simultaneously exerting toxic effects on healthy tissue.N^(6)-methyladenosine(m^(6)A),a prevalent modification on coding and non-coding RNAs,is a key epigenetic mark established by a set of evolutionarily conserved enzymes.The interplay between m^(6)A modification and radiobiology of cancerous and non-cancerous tissues merits in-depth investigation.This review summarizes the roles of m^(6)A in the biological effects induced by ionizing radiation and ultraviolet(UV)radiation.It begins with an overview of m^(6)A modification and its detection methods,followed by a detailed examination of how m^(6)A dynamically regulates the sensitivity of cancerous tissues to RT,the injury response in non-cancerous tissues,and the toxicological effects of UV exposure.Notably,this review underscores the importance of novel regulatory mechanisms of m^(6)A and their potential clinical applications in identifying epigenetically modulated radiation-associated biomarkers for cancer therapy and estimation of radiation dosages.In conclusion,enzyme-mediated m^(6)A-modification triggers alterations in target gene expression by affecting the metabolism of the modified RNAs,thus modulating progression and radiosensitivity in cancerous tissues,as well as radiation effects on normal tissues.Several promising avenues for future research are further discussed.This review highlights the importance of m^(6)A modification in the context of radiation biology.Targeting epi-transcriptomic molecules might potentially provide a novel strategy for enhancing the radiosensitivity of cancerous tissues and mitigating radiation-induced injury to normal tissues.
文摘Objective:To evaluate the pain degree of the patients with chronic non-cancer pain by using the evaluation model constituted by heart rate variability,anxiety and depression scale and quality of life rating scale.This study also aims toevaluate the efficacy after treatment and nursing intervention.Methods:100 patients with chronic non-cancer pain treated in the hospital from February 2016 to April 2017 were selected to compare their heart rate variability,score of anxiety and depression,score of quality of life and NRS score before and after treatment and nursing intervention.Results:After treatment and nursing intervention,the heart rate variability time domain SDNN significantly increased(P<0.05).The score of anxiety and depression was lower than that before intervention(P<0.05)while the scores of various dimensions of quality of life were higher than those before intervention(P<0.05).The results also showed that NRS score was lower than that before intervention(P<0.05).Conclusion:These findings suggest that the measurement combination of heart rate variability,anxiety and depression scale and quality of life rating scale can be used as an evaluation model to evaluate the pain degree of the patients with chronic non-cancer pain the efficacy after treatment and nursing intervention,which is worthy of clinic application.
基金supported by University of Macao(File No.MYRG-GRG2023-00160-ICMS-UMDF,China)the Science and Technology Development Fund,Macao SAR(File No.0015-2022-A1 and 005/2023/SKL,China)as well as the Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine,University of Macao(File No.SKL-QRCM-IRG2023-011,China).
文摘CD47 is an immune checkpoint widely regarded as a‘don't eat me’signal.CD47-based anti-cancer therapy has received considerable attention,with a significant number of clinical trials conducted.While anti-cancer therapies based on CD47 remain a focal point of interest among researchers,it is noteworthy that an increasing number of studies have found that CD47-based therapy ameliorated the pathological status of non-cancer diseases.This review aims to provide an overview of the recent progress in comprehending the role of CD47-based therapy in non-cancer diseases,including diseases of the circulatory system,nervous system,digestive system,and so on.Furthermore,we sought to delineate the promising mechanisms of CD47-based therapy in treating non-cancer diseases.Our findings suggest that CD47-based agents may exert their effect by regulating phagocytosis,regulating T cells,dendritic cells,and neutrophils,and regulating the secretion of cytokines and chemokines.Additionally,we put forward the orientation of further research to bring to light the potential of CD47 and its binding partners as a target in non-cancer diseases.
基金supported by grant 2022YFA1104001 from the National Key Research and Development Program of ChinaGrants Nos.82272745,81972966,82203433,82404099 and 82404113 from the National Natural Science Foundation of China+2 种基金grants BYSYZD2023010(to LXX),BYSY2022070(to YQW),BYSYZD2023041(to JLZ)and BYSYRCYJ2023004(to JLZ)from Peking University Third Hospital Clinical Key Projectgrant 2023A1515111068 from Basic and Applied Basic Research Foundation of Guangdong Provincegrant JCYJ20230807095121041 from Shenzhen Science and Technology Program.
文摘Enhancer of Zeste homolog 2(EzH2),a histone methyltransferase within polycomb repressive complex 2(PRC2),plays a crucial role in epigenetic regulation by silencing gene expression through trimethylation of histone 3 at lysine 27(H3K27me3).Beyond its well-documented oncogenic functions,emerging research has revealed EZH2's involvement in various non-cancerous pathologies.For instance,EZH2 is critical in regulating immune responses,particularly in modulating T cell differentiation and cytokine production,which affects inflammation and immune homeostasis.EzH2 also controls fibroblast activation and extracellular matrix(ECM)remodeling,influencing critical processes such as cell differentiation,tissue repair and energy homeostasis.Additionally,EzH2's epigenetic regulation of neuroinflammatory processes is linked to neuronal health and survival.Recent advancements in EZH2 inhibitor therapies demonstrate promising potential for treating a range of non-cancerous conditions,with preclinical trials suggesting efficacy in mitigating disease progression.This review highlights the expanding functional scope of EZH2,emphasizing its epigenetic mechanisms and the therapeutic opportunities for targeting EZH2 in non-cancerous diseases.
基金the Young Individual Research Grants(YIRG)(Grant No.A2084c0168)Singapore and A*STAR Central Funds(Grant No.C211718004),Singapore.
文摘Flexible polymeric patches find widespread applications in biomedicine because of their biological and tunable features including excellent patient compliance,superior biocompatibility and biodegradation,as well as high loading capability and permeability of drug.Such polymeric patches are classified into microneedles(MNs),hydrogel,microcapsule,microsphere and fiber depending on the formed morphology.The combination of nanomaterials with polymeric patches allows for improved advantages of increased curative efficacy and lowered systemic toxicity,promoting on-demand and regulated drug administration,thus providing the great potential to their clinic translation.In this review,the category of flexible polymeric patches that are utilized to integrate with nanomaterials is briefly presented and their advantages in bioapplications are further discussed.The applications of nanomaterials embedded polymeric patches in non-cancerous diseases were also systematically reviewed,including diabetes therapy,wound healing,dermatological disease therapy,bone regeneration,cardiac repair,hair repair,obesity therapy and some immune disease therapy.Alternatively,the limitations,latest challenges and future perspectives of such biomedical therapeutic devices are addressed.
文摘Liver transplantation (LT) is recognized as best treatment option in patients with early hepatocellular cancer (HCC) in underlying liver cirrhosis. Apart from tumor size and number implemented in the Milan criteria, which are current worldwide standards for patient selection, several biological tumor factors have been identified to affect cancer-specific outcome. In particular, grading and vascular tumor invasions were shown to correlate with aggressive biological tumor behavior and poor survival following LT. Identifying tumors with favorable biology is one important approach for expanding the pool of eligible liver recipients beyond the Milan burden limits. Improving the immunological state and condition for appropriate defense against circulating cancer cell attack may be another important prognostic aspect. Therefore, there is increasing interest in non-cancer factors related to the peritransplant period that may influence the oncological outcome by providing negative immunomodulatory actions. Considering and modulation of these non-HCC factors of prognosis might contribute in safely expanding the HCC LT selection criteria.
